Switch theme
Sign up to access all valuation multiples
Proteomics International Laboratories Ltd is a biological research and drug discovery company. The company specializes in the area of proteomics which is the industrial-scale study of the structure and function of proteins. Its operations are divided into PromarkerD which targets the diabetes epidemic and is a predictive diagnostic test for diabetic kidney disease, a progressive disorder found in one in three adults with diabetes; its proprietary biomarker discovery platform called Promarker, which searches for protein fingerprints in a sample; and Analytical Services that are specialist contract research focusing on biosimilars quality control and pharmacokinetic testing for clinical trials.
2014
n/a
LTM Revenue $2.4M
LTM EBITDA -$3.9M
$35.5M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Proteomics International has a last 12-month revenue of $2.4M and a last 12-month EBITDA of -$3.9M.
In the most recent fiscal year, Proteomics International achieved revenue of $0.6M and an EBITDA of -$5.3M.
Proteomics International expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Proteomics International valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $0.5M | $0.6M | XXX | XXX | XXX |
| Gross Profit | $0.9M | $0.5M | XXX | XXX | XXX |
| Gross Margin | 204% | 82% | XXX | XXX | XXX |
| EBITDA | -$5.2M | -$5.3M | XXX | XXX | XXX |
| EBITDA Margin | -1135% | -941% | XXX | XXX | XXX |
| Net Profit | -$3.1M | -$3.9M | XXX | XXX | XXX |
| Net Margin | -681% | -699% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Proteomics International's stock price is AUD 0 (or $0).
Proteomics International has current market cap of AUD 61.6M (or $38.7M), and EV of AUD 56.5M (or $35.5M).
See Proteomics International trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $35.5M | $38.7M | XXX | XXX | XXX | XXX | $-0.03 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Proteomics International has market cap of $38.7M and EV of $35.5M.
Proteomics International's trades at 15.1x LTM EV/Revenue multiple, and -9.1x LTM EBITDA.
Analysts estimate Proteomics International's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Proteomics International and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $35.5M | XXX | XXX | XXX |
| EV/Revenue | 24.1x | XXX | XXX | XXX |
| EV/EBITDA | -7.7x | XXX | XXX | XXX |
| P/E | -9.3x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -8.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpProteomics International's NTM/LTM revenue growth is 22%
Proteomics International's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.
Over next 12 months, Proteomics International's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Proteomics International's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Proteomics International and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 22% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -311% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 1% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -289% | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | n/a | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 622% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | 1123% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Zomedica | XXX | XXX | XXX | XXX | XXX | XXX |
| AnteoTech | XXX | XXX | XXX | XXX | XXX | XXX |
| Biohit | XXX | XXX | XXX | XXX | XXX | XXX |
| Genomictree | XXX | XXX | XXX | XXX | XXX | XXX |
| Avacta Group | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Proteomics International acquired XXX companies to date.
Last acquisition by Proteomics International was XXXXXXXX, XXXXX XXXXX XXXXXX . Proteomics International acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Proteomics International founded? | Proteomics International was founded in 2014. |
| Where is Proteomics International headquartered? | Proteomics International is headquartered in Australia. |
| Is Proteomics International publicy listed? | Yes, Proteomics International is a public company listed on ASX. |
| What is the stock symbol of Proteomics International? | Proteomics International trades under PIQ ticker. |
| When did Proteomics International go public? | Proteomics International went public in 2015. |
| Who are competitors of Proteomics International? | Similar companies to Proteomics International include e.g. Zomedica, AnteoTech, Biohit, Genomictree. |
| What is the current market cap of Proteomics International? | Proteomics International's current market cap is $38.7M |
| What is the current revenue of Proteomics International? | Proteomics International's last 12-month revenue is $2.4M. |
| What is the current EBITDA of Proteomics International? | Proteomics International's last 12-month EBITDA is -$3.9M. |
| What is the current EV/Revenue multiple of Proteomics International? | Current revenue multiple of Proteomics International is 15.1x. |
| What is the current EV/EBITDA multiple of Proteomics International? | Current EBITDA multiple of Proteomics International is -9.1x. |
| What is the current revenue growth of Proteomics International? | Proteomics International revenue growth between 2023 and 2024 was 22%. |
| Is Proteomics International profitable? | Yes, Proteomics International is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
